/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
OTTAWA, Nov. 7, 2018 /CNW/ - National Access Cannabis Corp. ("NAC" or the "Company") (TSXV: META) announces that it has amended and re-filed its unaudited reviewed interim financial statements and management's discussion and analysis (the "Filings") for the interim period ended May 31, 2018. The Filings have been amended to revise the accounting treatment for the acquisition of both National Access Cannabis Medical Inc. and NAC Bio Inc. The effect of the amendments to the Filings was to adjust the accounting treatment to consolidate both entities, adjusting the non-controlling interest and intangible assets.
About National Access Cannabis Corp.
NAC is a best practices leader in delivering secure, safe, and responsible access to legal cannabis in Canada. Through its Canada-wide network of medical cannabis clinics, partner pharmacies, NAC Bio Inc.'s clinical research division, Meta Cannabis Supply Co.™ and NewLeaf Cannabis™ recreational cannabis retail stores, NAC enables patients and the public to gain knowledge and access to Canada's network of authorized Licensed Producers of cannabis. NAC is listed on the TSX Venture Exchange under the symbol (TSXV: META).
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE National Access Cannabis Corp.
For further information: National Access Cannabis: Mark Goliger, Chief Executive Officer, National Access Cannabis, 1-800-411-1126, Info@nationalaccesscannabis.com; Investor Relations: Emily Gibbs, LodeRock Advisors Inc., 416-546-8775, firstname.lastname@example.org